GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurizon Therapeutics Ltd (FRA:ECQ0) » Definitions » Current Deferred Revenue

Neurizon Therapeutics (FRA:ECQ0) Current Deferred Revenue : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Neurizon Therapeutics Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Neurizon Therapeutics's current deferred revenue for the quarter that ended in Dec. 2023 was €0.00 Mil.

Neurizon Therapeutics Current Deferred Revenue Historical Data

The historical data trend for Neurizon Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurizon Therapeutics Current Deferred Revenue Chart

Neurizon Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Neurizon Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Neurizon Therapeutics Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Neurizon Therapeutics's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurizon Therapeutics Business Description

Traded in Other Exchanges
Address
96-100 Albert Road, Level 4, South Melbourne, Melbourne, VIC, AUS, 3205
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).

Neurizon Therapeutics Headlines

No Headlines